ArticleFrontiers in immunology2024

Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.

Wei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.